The treatment of methemoglobinemia consists of the intravenous administration of methylene blue that acts as a cofactor in the intra-erythrocyte reduction of methemoglobin in the presence of NADPH in non-G6PD-deficient subjects [1, 2, 4, 8]. This evidence concerns the gene HBG2 and methemoglobinemia.